The full analysis has yet to be completed, but initial findings from the breast cancer study appear positive as researchers begin enrolling for a third trial.
The team used CRISPR to inactivate a gene in colon organoids, and found that a specific DNA repair defect underlies a mutational signature in some cancers.
Researchers saw mismatch repair-related mutations in a significant subset of breast cancers, hinting at potential response to checkpoint blockade immunotherapy.
Genomic Health will gain exclusive worldwide rights to develop and sell an IVD version of its Oncotype DX breast cancer test on Biocartis' Idylla platform.
A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.
